CDKN2B and neoplasm: Notably we observed no redundancy in these checkpoint effector axes, meaning that any tumours harbouring inactivating mutations in any of the tumour suppressor genes namely p53, p21, Dkk3, ARF, Hdm2, FoxO3a, p15, p27 and Rb are susceptible to Cdc7 targeting agents.